Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. 903576-44-3
2. Ciproxidine
3. Bf 2649
4. Pitolisant Hcl
5. Pitolisant (hydrochloride)
6. Bf 2649 Hydrochloride
7. Yv33ch63hi
8. Pitolisant Hydrochloride [usan]
9. 1-(3-(3-(4-chlorophenyl)propoxy)propyl)piperidine Hydrochloride
10. Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-, Hydrochloride
11. 903576-44-3 (hcl)
12. Wakix (tn)
13. Pitolisant Hydrochloride (usan)
14. 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine Hydrochloride
15. 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine Hydrochloride
16. Piperidine, 1-(3-(3-(4-chlorophenyl)propoxy)propyl)-, Hydrochloride
17. Bf 2.649
18. Unii-yv33ch63hi
19. Schembl4591893
20. Bf-2649 Hydrochloride
21. Chembl4164059
22. Dtxsid50238098
23. Pitolisant;ciproxidine; Bf2649
24. Amy23423
25. Bcp16427
26. Ex-a1420
27. Hy-12199b
28. Pitolisant Hydrochloride [mi]
29. S5926
30. Akos024457784
31. Cs-1501
32. Sb17036
33. Pitolisant Hydrochloride [who-dd]
34. Ac-36017
35. As-72196
36. A3727
37. Pitolisant Hydrochloride [orange Book]
38. C77058
39. D11490
40. A900088
41. Q27895485
42. 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine;hydrochloride
43. 1-(3-(3-(4-chlorophenyl)propoxy)propyl)piperidine Monohydrochloride
44. Piperidine, 1-(3-(3-(4-chlorophenyl)propoxy)propyl)-, Hydrochloride (1:1)
Molecular Weight | 332.3 g/mol |
---|---|
Molecular Formula | C17H27Cl2NO |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 8 |
Exact Mass | 331.1469699 g/mol |
Monoisotopic Mass | 331.1469699 g/mol |
Topological Polar Surface Area | 12.5 Ų |
Heavy Atom Count | 21 |
Formal Charge | 0 |
Complexity | 235 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39721
Submission : 2024-04-01
Status : Active
Type : II
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
GDUFA
DMF Review : Complete
Rev. Date : 2023-05-19
Pay. Date : 2023-03-21
DMF Number : 38174
Submission : 2023-03-30
Status : Active
Type : II
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
GDUFA
DMF Review : Complete
Rev. Date : 2023-03-31
Pay. Date : 2023-03-15
DMF Number : 36859
Submission : 2022-03-01
Status : Active
Type : II
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : Complete
Rev. Date : 2023-07-28
Pay. Date : 2023-07-06
DMF Number : 37753
Submission : 2022-12-31
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-06-22
Pay. Date : 2023-04-21
DMF Number : 38307
Submission : 2023-05-09
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-08-22
Pay. Date : 2024-07-25
DMF Number : 39126
Submission : 2023-12-05
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-05-17
Pay. Date : 2023-04-25
DMF Number : 38131
Submission : 2023-03-27
Status : Active
Type : II
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
Date of Issue : 2024-02-20
Valid Till : 2026-12-06
Written Confirmation Number : WC-0416
Address of the Firm : Plot No. 111 SIDCO Industrial Estate, Kakkalur Thiruvallur-602003 Tamil Nadu, In...
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
NDC Package Code : 58159-084
Start Marketing Date : 2021-06-10
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (35kg/35kg)
Marketing Category : BULK INGREDIENT
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
NDC Package Code : 58159-092
Start Marketing Date : 2022-09-29
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (35kg/35kg)
Marketing Category : BULK INGREDIENT
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
NDC Package Code : 73435-034
Start Marketing Date : 2023-12-20
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 70966-0038
Start Marketing Date : 2019-08-14
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 14501-0114
Start Marketing Date : 2023-03-27
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
About the Company : Established in 2012, Nuray Chemicals Pvt Ltd is an API manufacturer for highly regulated markets. Its manufacturing facility with state-of-the-art R&D is located near Chennai in th...
About the Company : Emnar Pharma was established in 2005, with a drive to become the premier integrated pharmaceuticals company in India. Its business focuses on Contract Manufacturing, Custom Synthes...
About the Company : Virchow Group comprises of six active pharmaceutical ingredient (API) and drug intermediate manufacturing units and two biotech units. Incorporated in 1981, the flagship company of...
Details:
Wakix (pitolisant) is an oral H3 receptor antagonist/inverse agonist, small molecule drug. It is being evaluated for the treatment of narcolepsy in pediatric patients 6 years of age and older.
Lead Product(s): Pitolisant Hydrochloride
Therapeutic Area: Sleep Brand Name: Wakix
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2024
Lead Product(s) : Pitolisant Hydrochloride
Therapeutic Area : Sleep
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
HARMONY BIOSCIENCES Receives FDA Approval for WAKIX® in Pediatric Narcolepsy
Details : Wakix (pitolisant) is an oral H3 receptor antagonist/inverse agonist, small molecule drug. It is being evaluated for the treatment of narcolepsy in pediatric patients 6 years of age and older.
Brand Name : Wakix
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 24, 2024
Details:
Wakix (pitolisant) is an oral histamine-3 (H3) receptor antagonist/inverse agonist, small molecule drug. It is being evaluated for the treatment of Prader-Willi syndrome.
Lead Product(s): Pitolisant Hydrochloride
Therapeutic Area: Genetic Disease Brand Name: Wakix
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2024
Lead Product(s) : Pitolisant Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Harmony Biosciences Begins Global Phase 3 Trial of Pitolisant for Prader-Willi Syndrome
Details : Wakix (pitolisant) is an oral histamine-3 (H3) receptor antagonist/inverse agonist, small molecule drug. It is being evaluated for the treatment of Prader-Willi syndrome.
Brand Name : Wakix
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 03, 2024
Details:
Wakix (pitolisant) is an oral histamine-3 (H3) receptor antagonist/inverse agonist, small molecule drug. It is being evaluated for the treatment of Prader-Willi syndrome.
Lead Product(s): Pitolisant Hydrochloride
Therapeutic Area: Genetic Disease Brand Name: Wakix
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Lead Product(s) : Pitolisant Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Harmony Receives Orphan Drug Designation for Pitolisant in Prader-Willi Syndrome
Details : Wakix (pitolisant) is an oral histamine-3 (H3) receptor antagonist/inverse agonist, small molecule drug. It is being evaluated for the treatment of Prader-Willi syndrome.
Brand Name : Wakix
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 20, 2024
Details:
Wakix (pitolisant HCl) is a 5-HT3 receptor Inhibitor Small molecule drug candidate, which is currently being evaluated for the treatment of adult patients with myotonic dystrophy type 1.
Lead Product(s): Pitolisant Hydrochloride
Therapeutic Area: Genetic Disease Brand Name: Wakix
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2023
Lead Product(s) : Pitolisant Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Wakix (pitolisant HCl) is a 5-HT3 receptor Inhibitor Small molecule drug candidate, which is currently being evaluated for the treatment of adult patients with myotonic dystrophy type 1.
Brand Name : Wakix
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 07, 2023
Details:
Wakix (pitolisant hydrochloride) enhances the activity of histaminergic neurons and promotes wakefulness by blocking H3 autoreceptors and increasing the levels of histamine transmitters at the synapse and is being investigated for idiopathic hypersomnia.
Lead Product(s): Pitolisant Hydrochloride
Therapeutic Area: Sleep Brand Name: Wakix
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2023
Lead Product(s) : Pitolisant Hydrochloride
Therapeutic Area : Sleep
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Wakix (pitolisant hydrochloride) enhances the activity of histaminergic neurons and promotes wakefulness by blocking H3 autoreceptors and increasing the levels of histamine transmitters at the synapse and is being investigated for idiopathic hypersomnia.
Brand Name : Wakix
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 13, 2023
Details:
Wakix (pitolisant hydrochloride) enhances the activity of histaminergic neurons and promotes wakefulness by blocking H3 autoreceptors and increasing the levels of histamine transmitters at the synapse and is being investigated for idiopathic hypersomnia.
Lead Product(s): Pitolisant Hydrochloride
Therapeutic Area: Sleep Brand Name: Wakix
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Lead Product(s) : Pitolisant Hydrochloride
Therapeutic Area : Sleep
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Wakix (pitolisant hydrochloride) enhances the activity of histaminergic neurons and promotes wakefulness by blocking H3 autoreceptors and increasing the levels of histamine transmitters at the synapse and is being investigated for idiopathic hypersomnia.
Brand Name : Wakix
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 07, 2023
Details:
Wakix (pitolisant hydrochloride) enhances the activity of histaminergic neurons and promotes wakefulness by blocking H3 autoreceptors and increasing the levels of histamine transmitters at the synapse and is being investigated for Prader-Willi Syndrome.
Lead Product(s): Pitolisant Hydrochloride
Therapeutic Area: Genetic Disease Brand Name: Wakix
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2023
Lead Product(s) : Pitolisant Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Wakix (pitolisant hydrochloride) enhances the activity of histaminergic neurons and promotes wakefulness by blocking H3 autoreceptors and increasing the levels of histamine transmitters at the synapse and is being investigated for Prader-Willi Syndrome.
Brand Name : Wakix
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 20, 2023
Details:
Wakix (pitolisant) is a selective histamine 3 (H3) receptor antagonist/inverse agonist, which was granted orphan drug designation for the treatment of narcolepsy by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
Lead Product(s): Pitolisant Hydrochloride
Therapeutic Area: Sleep Brand Name: Wakix
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 04, 2023
Lead Product(s) : Pitolisant Hydrochloride
Therapeutic Area : Sleep
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
China NMPA Approves RareStone's Pitolisant (Wakix) for the Treatment of Narcolepsy
Details : Wakix (pitolisant) is a selective histamine 3 (H3) receptor antagonist/inverse agonist, which was granted orphan drug designation for the treatment of narcolepsy by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
Brand Name : Wakix
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 04, 2023
Details:
Wakix (pitolisant hydrochloride) enhances the activity of histaminergic neurons and promotes wakefulness by blocking H3 autoreceptors and increasing the levels of histamine transmitters at the synapse, which is used for Prader-Willi Syndrome.
Lead Product(s): Pitolisant Hydrochloride
Therapeutic Area: Genetic Disease Brand Name: Wakix
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2023
Lead Product(s) : Pitolisant Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Wakix (pitolisant hydrochloride) enhances the activity of histaminergic neurons and promotes wakefulness by blocking H3 autoreceptors and increasing the levels of histamine transmitters at the synapse, which is used for Prader-Willi Syndrome.
Brand Name : Wakix
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 06, 2023
Details:
Wakix (pitolisant hydrochloride) enhances the activity of histaminergic neurons and promotes wakefulness by blocking H3 autoreceptors and increasing the levels of histamine transmitters at the synapse.
Lead Product(s): Pitolisant Hydrochloride
Therapeutic Area: Sleep Brand Name: Wakix
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Lead Product(s) : Pitolisant Hydrochloride
Therapeutic Area : Sleep
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Wakix (pitolisant hydrochloride) enhances the activity of histaminergic neurons and promotes wakefulness by blocking H3 autoreceptors and increasing the levels of histamine transmitters at the synapse.
Brand Name : Wakix
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 25, 2023
Regulatory Info : RX
Registration Country : USA
Brand Name : WAKIX
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 4.45MG BASE
Packaging :
Approval Date : 2019-08-14
Application Number : 211150
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : WAKIX
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 17.8MG BASE
Packaging :
Approval Date : 2019-08-14
Application Number : 211150
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : Canada
Brand Name : WAKIX
Dosage Form : TABLET
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number : 2516241
Regulatory Info :
Registration Country : Canada
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Canada
Brand Name : WAKIX
Dosage Form : TABLET
Dosage Strength : 20MG
Packaging :
Approval Date :
Application Number : 2516268
Regulatory Info :
Registration Country : Canada
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Pitolisant Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pitolisant Hydrochloride, including repackagers and relabelers. The FDA regulates Pitolisant Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pitolisant Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Pitolisant Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Pitolisant Hydrochloride supplier is an individual or a company that provides Pitolisant Hydrochloride active pharmaceutical ingredient (API) or Pitolisant Hydrochloride finished formulations upon request. The Pitolisant Hydrochloride suppliers may include Pitolisant Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Pitolisant Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Pitolisant Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Pitolisant Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Pitolisant Hydrochloride DMFs exist exist since differing nations have different regulations, such as Pitolisant Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Pitolisant Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Pitolisant Hydrochloride USDMF includes data on Pitolisant Hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Pitolisant Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Pitolisant Hydrochloride suppliers with USDMF on PharmaCompass.
A Pitolisant Hydrochloride written confirmation (Pitolisant Hydrochloride WC) is an official document issued by a regulatory agency to a Pitolisant Hydrochloride manufacturer, verifying that the manufacturing facility of a Pitolisant Hydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Pitolisant Hydrochloride APIs or Pitolisant Hydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a Pitolisant Hydrochloride WC (written confirmation) as part of the regulatory process.
click here to find a list of Pitolisant Hydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Pitolisant Hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Pitolisant Hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Pitolisant Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Pitolisant Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Pitolisant Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Pitolisant Hydrochloride suppliers with NDC on PharmaCompass.
Pitolisant Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pitolisant Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pitolisant Hydrochloride GMP manufacturer or Pitolisant Hydrochloride GMP API supplier for your needs.
A Pitolisant Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Pitolisant Hydrochloride's compliance with Pitolisant Hydrochloride specifications and serves as a tool for batch-level quality control.
Pitolisant Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Pitolisant Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pitolisant Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Pitolisant Hydrochloride EP), Pitolisant Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pitolisant Hydrochloride USP).
LOOKING FOR A SUPPLIER?